Not Tagged
novocure
['lunar ']
#asco23 after 5y, the lunar study sample size was reduced from 534 to 276 patients. primary endpoint was os. half of pts with unknown pdl1 status. only 31% had prior immunotherapy. no mention of egfr/alk status. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo